Clinical observation of phased integrated traditional Chinese and Western medicine in the treatment of moderate and severe intrauterine adhesion with kidney deficiency and blood stasis

Clinical effect observation of kidney deficiency and blood stasis type of integrated Traditional Chinese and Western medicine by stages

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2022000024

Enrollment

Unknown

Registered

2022-06-22

Start date

2022-07-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intrauterine adhesions

Interventions

control group:Traditional Chinese medicine placebo (5% concentration of CAI Lianxiang empirical prescription for sequential oral administration)After TCRA, estradiol valerate + dydrogesterone tablets

Experimental group:CAI Lianxiang experienced the recipe Yiqi Xiaozheng Recipe and Yishen Zengmu Recipe+After TCRA, estradiol valerate + dydrogesterone tablets will be taken orally for 3 menstrual cycl

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of western medicine for intrauterine adhesions; (2) Meet the diagnostic criteria of traditional Chinese medicine for intrauterine adhesions with kidney deficiency and blood stasis syndrome; (3) Those who were diagnosed as moderate to severe adhesions during hysteroscopy (in the Chinese diagnostic grading standards for intrauterine adhesions) 9-18 points for severe adhesion and 19-28 points for severe adhesion); (4) Those with fertility requirements; (5) Age =40 years old.

Exclusion criteria

Exclusion criteria: (1) Congenital dysplasia of the uterus; combined with space-occupying lesions in the uterine cavity, such as submucosal fibroids or endometrial polyps; (2) ovulatory infertility; (3) oligomenorrhea caused by low ovarian function; (4) undiagnosed Vaginal bleeding (5) known or suspected breast cancer; known or suspected precancerous lesions or malignant tumors affected by sex hormones; (6) current or past history of liver tumors (benign or malignant); (7) acute arterial thromboembolism, active venous thrombosis Formation, thromboembolic disease or medical history, high risk factors for venous or arterial thrombosis; ? severe hypertriglyceridemia; ? combined with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system; suspected mental patients; ? for Those who are allergic to the study drug or any excipients;

Design outcomes

Primary

Measure	Time frame
Classification and score of intrauterine adhesions;	—

Secondary

Measure	Time frame
Menstrual blood volume;Chinese medicine symptom complex score;endometrial receptivity;	—

Countries

CHINA

Contacts

Public ContactFuli Zhu

Xiyuan Hospital,China Academy of Chinese Medical Sciences

zhufl@sina.com13521431579

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026